RxDoctor Payments DataLook up a doctor →

Sarah Jamieson, PA

Medical · Frederick, MDNPI 1295813319

Payments from drug & device makers

$34,242in general payments, 2019–2025

Across 848 payments — averaging $40.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$9K
  • Lilly USA, LLC$6K
  • Biohaven Pharmaceuticals, Inc.$3K
  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • Novartis$2K
  • Axsome Therapeutics, Inc.$1K
  • plus $10K from 44 others

What the payments were for

  • Speaking & faculty fees$18,40954%
  • Grants$440%
  • Travel & lodging$3241%
  • Food & beverage$15,05944%
  • Education$4061%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,242 in reported general payments places this provider in the 95th percentile of 543 medical providers in Maryland.

See all medical providers in Maryland

Medicare billing

Part B allowed, 2024
$16,589
Medicare patients
102
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab13$196,601
UbrelvyUbrogepant29$34,213
QuliptaAtogepant16$15,039
SunosiSolriamfetol Hcl14$11,309
Zolpidem Tartrate ErZolpidem Tartrate84$3,266
Armodafinil42$2,535
Carbamazepine ErCarbamazepine29$2,398
Modafinil28$2,297
Doxepin Hcl22$1,941
Baclofen46$1,818
Pregabalin27$1,805
Eszopiclone54$1,633
Gabapentin89$1,254
Zolpidem Tartrate169$1,087
Triazolam21$1,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$9,378$49,25145 claims
Axsome Therapeutics, Inc.Sunosi$1,198$11,30914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 543 medical providers in Maryland.

Other medical in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →